1. Treatment of ovarian cancer beyond chemotherapy: Are we hitting the target?

   • Álvaro Henrique Ingles Garces
   • Mariane Sousa Fontes Dias
   • Andréia Cristina de Melo

   Review Article 12 September 2014 Pages: 221 - 234

2. Prognostic relevance of carbonic anhydrase IX expression is distinct in various subtypes of breast cancer and its silencing suppresses self-renewal capacity of breast cancer cells

   • Lāsma Ivanova
   • Elīna Zandberga
   • Aija Linē

   Original Article 25 November 2014 Pages: 235 - 246

   

3. Intravenous 3-weekly paclitaxel and metronomic oral cyclophosphamide in patients with advanced urothelial cancer previously treated with gemcitabine and platinum

   • Ji Hyun Park
   • Jae-Lyun Lee

   Original Article 27 November 2014 Pages: 247 - 254

   

4. Preoperative neutrophil-to-lymphocyte ratio predicts response to first-line platinum-based chemotherapy and prognosis in serous ovarian cancer

   • Ying Wang
   • Ping Liu
   • Hong Ni

   Original Article 27 November 2014 Pages: 255 - 262

   

5. Antitumor efficacy of tangeretin by targeting the oxidative stress mediated on 7,12-dimethylbenz(a) anthracene-induced proliferative breast cancer in Sprague–Dawley rats

   • Kuppusamy Periyasamy
   • Kuppusamy Baskaran
   • Dhanapal Sakthisekaran

   Original Article 28 November 2014 Pages: 263 - 272

   

6. Pre-treatment serum total bilirubin level as an indicator of optimal CPT-11 dosage

   • Katsuya Makihara
   • Sayaka Azuma
   • Izumi Nakata

   Original Article 29 November 2014 Pages: 273 - 279

   

7. Cellular uptake kinetics of bortezomib in relation to efficacy in myeloma cells and the influence of drug transporters

   • Jannick Clemens
   • Anja Seckinger
   • Johanna Weiss

   Original Article 05 December 2014 Pages: 281 - 291

   

8. A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002)

   • Masashi Kanai
   • Etsuro Hatano
   • Tatsuya Ioka

   Original Article 05 December 2014 Pages: 293 - 300

   

9. Efficacy of neo-adjuvant chemotherapy with TEC regimen on breast cancer

   • Xi Gu
   • Yang Zhang
   • Wen-Hai Zhang

   Original Article 06 December 2014 Pages: 301 - 308

10. A Phase I study of cabazitaxel in patients with advanced gastric cancer who have failed prior chemotherapy (GASTANA)

    • Yoon-Koo Kang
    • Baek-Yeol Ryoo
    • Min-Hee Ryu

    Original Article 09 December 2014 Pages: 309 - 318

    

11. Phase II trial of miniDOX (reduced dose docetaxel–oxaliplatin–capecitabine) in “suboptimal” patients with advanced gastric cancer (AGC). TTD 08-02

    • F. Rivera
    • B. Massutí
    • E. Aranda

    Original Article 10 December 2014 Pages: 319 - 324

    

12. Phase II study evaluating efficacy and safety of everolimus with letrozole for management of advanced (unresectable or metastatic) non-small cell lung cancer after failure of platinum-based treatment: a preliminary analysis of toxicity

    • Nimit Singhal
    • Sina Vatandoust
    • Michael P. Brown

    Original Article 11 December 2014 Pages: 325 - 331

    

13. Pharmacokinetic/pharmacodynamic-based decision making in the development of MK-0888, a VEGFR-2/FLT-3 kinase inhibitor

    • Marian Iwamoto
    • Evan J. Friedman
    • John A. Wagner

    Original Article 19 December 2014 Pages: 333 - 342

    

14. A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors

    • Hope E. Uronis
    • Jingquan Jia
    • Herbert I. Hurwitz

    Original Article 20 December 2014 Pages: 343 - 352

    

15. Oxymatrine targets EGFR^p-Tyr845 and inhibits EGFR-related signaling pathways to suppress the proliferation and invasion of gastric cancer cells

    • Bingyu Guo
    • Tingting Zhang
    • Xiaoming Li

    Original Article 20 December 2014 Pages: 353 - 363

    

16. Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules

    • P. Hamberg
    • R. H. J. Mathijssen
    • M. J. A. de Jonge

    Original Article 23 December 2014 Pages: 365 - 371

    

17. A phase 1 multiple-dose study of orteronel in Japanese patients with castration-resistant prostate cancer

    • Kazuhiro Suzuki
    • Seiichiro Ozono
    • Hideyuki Akaza

    Original Article Open access 24 December 2014 Pages: 373 - 380

18. Novel FTS-diamine/cinnamic acid hybrids inhibit tumor cell proliferation and migration and promote apoptosis via blocking Ras-related signaling in vitro

    • Yong Ling
    • Xinmei Zhao
    • Yihua Zhang

    Original Article 27 December 2014 Pages: 381 - 392

    

19. Prevalence and clinical significance of potential drug–drug interaction in hematopoietic stem cell transplantation

    • Danilo D. Trevisan
    • Juliana B. Silva
    • Maria Helena M. Lima

    Original Article 27 December 2014 Pages: 393 - 400

20. Onartuzumab with or without bevacizumab in combination with weekly paclitaxel does not prolong QTc or adversely affect other ECG parameters in patients with locally recurrent or metastatic triple-negative breast cancer

    • Marie T. Borin
    • Meng Chen
    • Mark Stroh

    Original Article 27 December 2014 Pages: 401 - 410

    

21. Cks1 proteasomal degradation is induced by inhibiting Hsp90-mediated chaperoning in cancer cells

    • Vinayak Khattar
    • Joshua Fried
    • Jaideep V. Thottassery

    Original Article 28 December 2014 Pages: 411 - 420

    

22. CEACAM1 and hollow spheroid formation modulate the chemosensitivity of colorectal cancer to 5-fluorouracil

    • Naoyuki Yamamoto
    • Shozo Yokoyama
    • Hiroki Yamaue

    Original Article 30 December 2014 Pages: 421 - 430

    

23. Novel in silico-designed estradiol analogues are cytotoxic to a multidrug-resistant cell line at nanomolar concentrations

    • Anne Theron
    • Renaud Prudent
    • Annie Joubert

    Short Communication 30 December 2014 Pages: 431 - 437